Moreover, the findings of a different ER expression in pituitary adenomas could also generate the development of a highly specific ERβ agonist to regulate GH secretion in somatotropinomas, as recently discovered for the treatment of ovarian cancer [86,87]. Here, ESR2 is linked to growth hormone-producing pituitary gland neoplasm.